Massage might help your brain flow regain its mojo. On June 4 in Nature, researchers led by Gou Young Koh at the Institute for Basic Science in Daejeon, South Korea, mapped the labyrinth of lymphatics ...

For years, scientists have been working toward blood tests for Alzheimer’s disease that could be used routinely in clinical practice. Now, they are on the cusp. At this year’s ADPD conference, held ...

Seeking ways to improve the safety of anti-amyloid antibodies, John Sims of Eli Lilly & Company presented a simple option to do so for donanemab at this year’s Clinical Trials on Alzheimer’s Disease ...

Old drugs die hard. Despite a string of negative Phase 3 trials, HMTM, a derivative of the malaria drug methylene blue, resurfaced again at AD/PD 2024, held March 5-9 in Lisbon, Portugal. TauRx CEO ...

Studies aim to validate Alzheimer's disease blood tests against gold standard biomarkers in primary care. Scientists ask how best to incorporate AD blood tests into existing healthcare systems. Some ...

All Signs Point to Plaque Clearance Tangle accumulation has slowed in all successful anti-amyloid antibody trials so far—except in the Trailblazer-Alz2 study of donanemab. That trial posted the ...

Trontinemab rapidly clears plaque with little ARIA. Potentially, this is because its direct brain delivery method sidesteps vascular amyloid. Breaching the blood-brain barrier via ultrasound also ...

The first direct-to-consumer Alzheimer’s disease blood test has arrived. Quest Diagnostics, a worldwide diagnostic service headquartered in Secaucus, New Jersey, announced on July 31 that it would ...

They homed in on an inflammatory reaction to cerebral amyloid angiopathy. CAA experts noted that ARIA-E resembles CAA-related inflammation, a rare and serious condition caused by auto-antibodies to Aβ ...

Joachim Herz of the University of Texas Southwestern Medical Center, Dallas, who has studied Reelin in the brain for decades, was unsurprised that a variant was protective, though the magnitude of ...

Michelle Mielke at Wake Forest University in Winston-Salem, North Carolina, noted that women’s higher risk is likely to have multiple causes. “Hormones are a contributor, but there are a lot of other ...

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...